These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8688836)

  • 21. Optimal drug regimens in cancer chemotherapy for single drugs that block progression through the cell cycle.
    Murray JM
    Math Biosci; 1994 Oct; 123(2):183-213. PubMed ID: 7827419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Developments and problems of cytostatic chemotherapy].
    Gross R
    Internist (Berl); 1971; 12():Suppl 1:109-15. PubMed ID: 4944099
    [No Abstract]   [Full Text] [Related]  

  • 23. [Current status of anticancer chemotherapy. Progress in concept, methods and means].
    Chauvergne J
    Rev Laryngol Otol Rhinol (Bord); 1977; 98(5-6):271-89. PubMed ID: 897407
    [No Abstract]   [Full Text] [Related]  

  • 24. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor.
    Davis AJ; Tannock JF
    Lancet Oncol; 2000 Oct; 1():86-93. PubMed ID: 11905673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A; Mishra L; Li S
    Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling tumor growth.
    Calderón CP; Kwembe TA
    Math Biosci; 1991 Feb; 103(1):97-114. PubMed ID: 1804444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor micro-ecology and competitive interactions.
    Michelson S; Miller BE; Glicksman AS; Leith JT
    J Theor Biol; 1987 Sep; 128(2):233-46. PubMed ID: 3431136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
    Cho H; Levy D
    J Theor Biol; 2018 Jan; 436():120-134. PubMed ID: 29030212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative model for multiple levels of drug resistance in clinical tumors.
    Goldie JH; Coldman AJ
    Cancer Treat Rep; 1983 Oct; 67(10):923-31. PubMed ID: 6627236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mathematical modelling: Forecasting cancer.
    Gammon K
    Nature; 2012 Nov; 491(7425):S66-7. PubMed ID: 23320294
    [No Abstract]   [Full Text] [Related]  

  • 31. Cancer chemotherapy: optimal control using the Verhulst-Pearl equation.
    Swan GW
    Bull Math Biol; 1986; 48(3-4):381-404. PubMed ID: 3828564
    [No Abstract]   [Full Text] [Related]  

  • 32. Interactions between tumor cell subpopulations in malignant tumors.
    Poste G; Greig R; Tzeng J; Koestler T; Corwin S
    Symp Fundam Cancer Res; 1983; 36():223-43. PubMed ID: 6382506
    [No Abstract]   [Full Text] [Related]  

  • 33. A bilinear control model for tumor growth and chemotherapy.
    Vaidya VG; Alexandro FJ; Vaidya PG
    Int J Biomed Comput; 1985 Sep; 17(2):145-54. PubMed ID: 4055120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy.
    Jackson TL; Byrne HM
    Math Biosci; 2000 Mar; 164(1):17-38. PubMed ID: 10704636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model.
    Barbolosi D; Iliadis A
    Comput Biol Med; 2001 May; 31(3):157-72. PubMed ID: 11173054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rationalization of adjuvant chemotherapy by induction chemotherapy].
    Hoerni B; Chauvergne J
    Bull Cancer; 1984; 71(4):297-300. PubMed ID: 6498345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bleomycin in combination chemotherapy of metastatic Wilms tumor: a late recurrent case, refractory to conventional therapy.
    Kisielius T; Bianco A; Merrill JM; Taylor SG; DeWys W
    Med Pediatr Oncol; 1979; 6(1):11-4. PubMed ID: 86941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Some optimal control problems in cancer chemotherapy with a toxicity limit.
    Murray JM
    Math Biosci; 1990 Jun; 100(1):49-67. PubMed ID: 2134468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating and designing cancer chemotherapy treatment using mathematical models.
    Birkhead BG; Gregory WM; Slevin ML; Harvey VJ
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):3-8. PubMed ID: 3956557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.